Skip to main content

Table 3 Distribution of TLR4 alleles and genotypes Vitiligo patients and healthy controls (group 1: below 18 years)

From: TLR4 gene polymorphisms in Egyptian vitiligo patients: insights into emerging association with clinical activity, family history, and response to therapy

TLR4 polymorphisms Case (N—24) N (%) Control (N = 19)
N (%)
OR (95% CI) p/pc
rs1927914 (C/T)
CC 3 (12.5) 0 (00.0) 1.91 (1.41–2.56) 0.24/NS
CT 3 (12.5) 4 (21.1) 0.54 (0.10–2.75) 0.68/NS
TT 18 (75.0) 15 (78.9) 1.25 (0.29–5.27) 0.76/NS
C 9 (18.7) 4 (10.5) 1.96 (0.55–6.95) 0.37/NS
T 39 (81.3) 34 (89.5) 0.51 (0.14–1.81) 0.37/NS
rs1927911 (C/T)
CC 4 (16.7) 2 (10.5) 1.70 (0.28–10.4) 0.68/NS
CT 15 (62.5) 16 (84.5) 0.31 (0.07–1.38) 0.12/NS
TT 5 (20.8) 1 (5.30) 0.21 (0.02–1.99) 0.21/NS
C 23 (48.0) 20 (52.6) 0.82 (0.35–1.94) 0.66/NS
T 25 (52.0) 18 (47.4) 1.21 (0.52–2.83) 0.66/NS
rs11536858 (A/G)
AA 5 (20.8) 5 (26.3) 0.74 (0.18–3.05) 0.67/NS
AG 17 (70.8) 9 (47.4) 2.69 (0.77–9.51) 0.12/NS
GG 2 (8.30) 5 (26.3) 0.93 (0.39–2.21) 0.21/NS
A 27 (54.6) 19 (50.0) 1.29 (0.54–3.02) 0.56/NS
G 21 (45.4) 19 (50.0) 0.78 (0.33–1.83) 0.56/NS
  1. OR odds ratio, 95%CI 95% confidence interval
  2. Significant p/pc values if < 0.05, pc Bonferroni corrected p value (number of comparison × p value). NS non-significant
  3. Fisher’s exact: no significant relations have been found between the alleles and genotypes (p > 0.05)